Concepedia

Publication | Open Access

Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study

DOIFull Paper Access

46

Citations

17

References

2013

Year

Jeffrey R. Infante, Tony R. Reid, Allen Lee Cohn, William J. Edenfield, Terrence P. Cescon, John Hamm, Imtiaz A. Malik, Thomas A. Rado, Philip J. McGee, Donald Richards,
Cancer

Abstract

Neither the addition of continuous axitinib nor the axitinib/bevacizumab combination to FOLFOX-6 improved ORR, PFS, or OS compared with bevacizumab as first-line treatment of mCRC.

References

YearCitations

Page 1